Tag:
TC-5214
Latest Headlines
Latest Headlines
Targacept slashes staff by half in wake of PhIII disaster
The late-stage collapse of Targacept's depression drug--TC-5214--will cost the jobs of close to half of the biotech's staffers, with 65 workers getting pink slips today.
Final PhIII results wipe out AstraZeneca, Targacept depression drug
AstraZeneca ( $AZN ) and Targacept ( $TRGT ) made it official today that their partnered depression drug--TC-5214--proved a complete bust in Phase III.
AstraZeneca buries one program as second drug stumbles again in PhIII
AstraZeneca ( $AZN ) has back-to-back setbacks to report on a pair of key drug development programs. The pharma giant reported that it's burying the ovarian cancer drug program for olaparib after
Key antidepressant from AZ/Targacept fails trial
The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's ( $AZN ) struggling R&D operation another stinging setback and walloping
Key AZ/Targacept depression drug flunks first Phase III test
The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's struggling R&D operation another stinging setback and walloping Targacept
AZ drops its option on Targacept schizophrenia program
Targacept is being forced to write off another potentially lucrative partnership deal. Staring at a $30 million payment, AstraZeneca has decided to walk away from its option to develop an
Targacept scores blockbuster $1.2B deal with AZ
Backed up with some impressive mid-stage data, Targacept has inked a $1.24 billion licensing deal with AstraZeneca for its promising new depression therapy. The Winston-Salem, NC-based developer
Targacept touts mid-stage depression drug results
More good news for Targacept: the company has announced favorable results from a Phase II trial of TC-5214 as an add-on treatment for major depressive disorder in subjects who did not respond to
